Molecular Diagnostic Platform for AML
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 2000
- Registration Number
- NCT04446741
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain
🇪🇸Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
🇪🇸Hospital Doce de Octubre, Madrid, Spain
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT04443751
- Locations
- 🇨🇳
Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
- Conditions
- MYELODYSPLASTIC SYNDROME; MDSACUTE MYELOID LEUKEMIA; AML
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04429191
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT04402723
- Locations
- 🇨🇳
Institute of Hematology and Blood Disease Hospital, Tianjin, Tianjin, China
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
- Conditions
- Myelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Kiadis Pharma
- Registration Number
- NCT04395092
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸MD Anderson, Houston, Texas, United States
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 65
- Registration Number
- NCT04373395
- Locations
- 🇨🇳
the First Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
- Conditions
- Acute Lymphoblastic Leukemia (ALL) in Complete RemissionAcute Myeloid Leukemia (AML) in Remission
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 264
- Registration Number
- NCT04314219
- Locations
- 🇸🇦
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- NexImmune Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04284228
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Advent Health Medical Group Blood & Marrow Transplant, Orlando, Florida, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04275518
- Locations
- 🇨🇳
The First Hospital of Peking University, Beijing, Beijing, China
🇨🇳Guangzhou panyu central hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
- Conditions
- Non Small Cell Lung CancerCancerAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT04272203
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc /ID# 224332, Fort Wayne, Indiana, United States
🇺🇸Gabrail Cancer Center Research /ID# 215667, Canton, Ohio, United States
🇺🇸Thomas Jefferson University /ID# 218403, Philadelphia, Pennsylvania, United States